Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 738.02M P/E - EPS this Y -16.30% Ern Qtrly Grth -
Income -104.56M Forward P/E -5.13 EPS next Y -12.00% 50D Avg Chg 2.00%
Sales 20.45M PEG 0.54 EPS past 5Y - 200D Avg Chg 15.00%
Dividend N/A Price/Book 2.52 EPS next 5Y -15.90% 52W High Chg -32.00%
Recommedations 1.70 Quick Ratio 32.06 Shares Outstanding 51.70M 52W Low Chg 236.00%
Insider Own 3.50% ROA -17.29% Shares Float 30.88M Beta 2.93
Inst Own 110.44% ROE -25.53% Shares Shorted/Prior 9.62M/9.32M Price 17.89
Gross Margin - Profit Margin - Avg. Volume 551,431 Target Price 52.30
Oper. Margin -136,200.00% Earnings Date Aug 7 Volume 396,220 Change 0.39%
About 4D Molecular Therapeutics, Inc.

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.

4D Molecular Therapeutics, Inc. News
05/11/24 We're Interested To See How 4D Molecular Therapeutics (NASDAQ:FDMT) Uses Its Cash Hoard To Grow
05/11/24 4D Molecular Therapeutics First Quarter 2024 Earnings: US$0.66 loss per share (vs US$0.88 loss in 1Q 2023)
05/10/24 4D Molecular Therapeutics Inc (FDMT) Q1 2024 Earnings: Misses Analyst Net Income Projections
05/09/24 4DMT Reports First Quarter 2024 Financial Results and Operational Highlights
05/07/24 4DMT to Participate in Upcoming Investor Conference
05/01/24 4D Molecular Therapeutics, Inc. (FDMT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
05/01/24 4DMT Announces Presentations at ARVO 2024 Annual Meeting
04/04/24 4D Molecular Therapeutics Inc (FDMT) Chief Legal Officer Scott Bizily Sells 8,153 Shares
03/29/24 4D Molecular Therapeutics Inc's Chief Legal Officer Sells Company Shares
03/28/24 4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis
03/04/24 4DMT to Participate in Upcoming Investor Conferences
03/03/24 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
03/02/24 4D Molecular Therapeutics Full Year 2023 Earnings: Misses Expectations
03/02/24 4D Molecular Therapeutics Inc Reports Full Year 2023 Financial Results
02/29/24 4D Molecular Therapeutics, Inc. (FDMT) Reports Q4 Loss, Misses Revenue Estimates
02/29/24 4DMT Reports Full Year 2023 Financial Results and Operational Highlights
02/26/24 Strength Seen in Lyra Therapeutics, Inc. (LYRA): Can Its 6.9% Jump Turn into More Strength?
02/12/24 4DMT Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials for Fabry Disease Cardiomyopathy at WORLDSymposium™ 2024
02/12/24 Institutional investors in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) lost 11% last week but have reaped the benefits of longer-term growth
02/08/24 Chief Medical Officer Robert Kim Sells Shares of 4D Molecular Therapeutics Inc
FDMT Chatroom

User Image DameWave Posted - 6 days ago

$FBIO How long can this go on? If you buy shares in FBIO now, you get 53% of DERM, $7 M (because 53% of DERM is valued $7 M higher than the entire FBIO) and the remaining portfolio below valued at $0. Again, $0... In addition to the ownership %, FBIO has a 2.5% annual equity dividend and 4.5% royalty in almost all below... * = Deals made - Helocyte – 83% - Cellvation – 79% - Oncogenuity – 79% - *Cyprium – 74% (PRV $110 M + $20 M approval and eligible to receive sales milestones totaling up to $129 M and tiered royalties: 3.00% of net sales up to $75 M, 8.75% between $75 M and $100 M, 12.50% over $100 M up to $255-275 M in total) - Urica – 68% - *Caelum – 42% ($31,8 M on approval and up to ~$150 M in future proceeds from $AZN deal) - *Aevitas - ? (eligible to ~$140 M in potential late-stage development, regulatory and sales milestone payments plus royalties from $FDMT) - Mustang – 21% Checkpoint – 11% - Avenue – 4% $XBI $IBB

User Image erevnon Posted - 6 days ago

HC Wainwright & Co. reiterates 4D Molecular Therapeutics $FDMT at Buy and maintains a price target of https://marketsblock.com/stock-upgrades-and-downgrades/

User Image jewell69 Posted - 1 week ago

been investing on advice from Gena Wang; 5/10 In a report released today, Gena Wang from Barclays maintained a Buy rating on 4D Molecular Therapeutics (FDMT – Research Report), with a price target of $45.00. The company’s shares closed yesterday at $25.64. Wang covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Legend Biotech, and Vertex Pharmaceuticals. According to TipRanks, Wang has an average return of 9.1% and a 45.66% success rate on recommended stocks. $FDMT

User Image DameWave Posted - 1 week ago

$FBIO Q1 och ARVO presentation update from $FDMT about 4D-175 “Under the terms of the agreement, 4DMT will make cash payments to Aevitas totaling up to ~$140 million in potential late-stage development, regulatory and sales milestones. A range of single-digit royalties on net sales are also payable.” https://www.fortressbiotech.com/news-media/press-releases/detail/528/aevitas-therapeutics-a-fortress-biotech-subsidiary “Building on the success of intravitreal R100, we are also encouraged by the preclinical results from 4D-175 that we shared today at the 2024 Association for Research in Vision and Ophthalmology (ARVO) Annual Scientific Meeting and are looking forward to bringing the program into the clinic for treatment of geographic atrophy in the second half of the year, demonstrating the power of our modular vectors and product engine.” https://ir.4dmoleculartherapeutics.com/news-releases/news-release-details/4dmt-reports-first-quarter-2024-financial-results-and https://4dmoleculartherapeutics.com/wp-content/uploads/Presentation_ARVO-2024_Calton_4D-175-Preclinical-Characterization_Final_20Apr2024.pdf IND filing expected in Q2 2024 Phase 1 initiation expected in H2 2024 $XBI $IBB

User Image Stock_Titan Posted - 1 week ago

$FDMT 4DMT Reports First Quarter 2024 Financial Results and Operational Highlights https://www.stocktitan.net/news/FDMT/4dmt-reports-first-quarter-2024-financial-results-and-operational-uxau4uryxfo8.html

User Image ctenidae Posted - 1 week ago

@neofeudal Selling Cimerli was brilliant- the gene therapies coming from $ADVM and $FDMT and longer-acting implants like $EYPT are going to crush the monthly injections. Cimerli is a rapidly melting ice cube- I'm glad they got rid of it, and cleaned out problematical debt at the same time. I'm calling management smart here.

User Image bubbybubster Posted - 2 weeks ago

$XBI rotated 20% of my portfolio out of energy to go heavy-weight on biotech last week. good move $FDMT $BBIO $SRRK

User Image Stock_Titan Posted - 2 weeks ago

$FDMT 4DMT Announces Presentations at ARVO 2024 Annual Meeting https://www.stocktitan.net/news/FDMT/4dmt-announces-presentations-at-arvo-2024-annual-oqtxqvok08iy.html

User Image Fullratio Posted - 04/25/24

Healthcare sector stocks with high YoY gross profit growth in Q4 2023: $CLSD $FDMT $BEAM

User Image jewell69 Posted - 04/23/24

$LEGN just bot 100 at 36.30 just 2 b prudent, canceled buy order of 201 $FDMT at 25.04

User Image jewell69 Posted - 04/23/24

$FDMT tryin 2 buy 201 at 25.04

User Image jewell69 Posted - 04/22/24

04/22/2024 15:48:59 Sold 200 FDMT @ 26.3101 5,261.95 0.00 0.07 04/17/2024 10:12:13 Bought 200 FDMT @ 26 -5,200.00 $FDMT Grandpa calls it a pyrrhic victory. Not sure what that means, but it doesnt sound good. new topic $BABA 04/22/2024 11:27:55 Sold 200 BABA @ 70.1301 14,025.88 0.00 0.14 04/16/2024 09:33:06 Bought 200 BABA @ 70 -14,000.00

User Image bubbybubster Posted - 04/22/24

top biotechs with upcoming catalysts and promising pipelines $BBIO $FDMT $SRRK

User Image bubbybubster Posted - 04/22/24

$FDMT got another 3k shares under 25. 6k shares @ 26.66 average

User Image Fullratio Posted - 1 month ago

Healthcare sector stocks with high YoY revenue growth in Q4 2023: $FDMT $PAVM $BEAM

User Image insiderbuyingselling Posted - 1 month ago

$FDMT new insider selling: 1750 shares. http://insiderbuyingselling.com/?t=FDMT

User Image DameWave Posted - 1 month ago

$FBIO FBIO is eligible to receive up to ~$140 M in potential late-stage development, regulatory and sales milestone payments plus royalties from $FDMT after the Aevitas Therapeutics deal. Keep an eye on their promising R100 platform in ophthalmology and especially 4D-175 that the deal is about. $XBI https://seekingalpha.com/news/4089674-4d-molecular-therapeutics-new-overweight-barclays-genetic-medicine-platform

User Image jewell69 Posted - 1 month ago

Ms gena Wang "assigned" $FDMT after hours gtc tryin 2 buy 26. 00 4/16 close 26.75 her pt 45 tipRanks says stron buy 10 buys, 0 holds, 0 sells

User Image traderstatusquo_ Posted - 1 month ago

$FDMT buyer in low $20’s

User Image bubbybubster Posted - 1 month ago

$FDMT bought the dip. 2000 shares @ 28.50 to start

User Image insiderbuyingselling Posted - 03/29/24

$FDMT new insider selling: 5833 shares. http://insiderbuyingselling.com/?t=FDMT

User Image Stock_Titan Posted - 03/28/24

$FDMT 4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis https://www.stocktitan.net/news/FDMT/4dmt-announces-update-on-regulatory-interactions-and-development-g2qu5csoqfob.html

User Image Gmo_ Posted - 03/27/24

$FDMT long hold this will continue higher

User Image StockInvest_us Posted - 03/25/24

Signal alert: $FDMT - Overbought Trend Short (Overvalued) https://stockinvest.us/l/c5llwcwWrw

User Image StockConsultant Posted - 2 months ago

$FDMT 4D Molecular Therapeutics stock, solid breakout , see https://stockconsultant.com/?FDMT

User Image AnomalyDetective Posted - 2 months ago

Week 12 MDA picks have just been released for members with 1 out 4 picks already up over 12.4% from selection despite rising negative Momentum Gauge® values in warning signal for markets at http://vmbreakouts.com The count of weekly breakout picks gaining over 10% continues to 280 weeks. Prior recent picks $LAC $FDMT continue higher but use caution as market outflows are increasing.

User Image vjtweet Posted - 2 months ago

$FDMT long above 30

User Image Pancho_Trader Posted - 2 months ago

$FDMT That VWAP line was getting too obvious

User Image Stock_Titan Posted - 2 months ago

$FDMT 4DMT to Participate in Upcoming Investor Conferences https://www.stocktitan.net/news/FDMT/4dmt-to-participate-in-upcoming-investor-4vc8cuqytcn8.html

User Image insiderbuyingselling Posted - 02/29/24

$FDMT new insider selling: 1909 shares. http://insiderbuyingselling.com/?t=FDMT

Analyst Ratings
HC Wainwright & Co. Buy May 13, 24
RBC Capital Outperform Apr 15, 24
Barclays Overweight Apr 15, 24
BMO Capital Outperform Apr 1, 24
Jefferies Buy Apr 1, 24
HC Wainwright & Co. Buy Mar 1, 24
BMO Capital Outperform Feb 5, 24
RBC Capital Outperform Feb 5, 24
RBC Capital Outperform Jan 29, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Kirn David Chief Executive Offi.. Chief Executive Officer Jan 23 Sell 18.4079 5,696 104,851 1,151,154 01/25/24
VIKING GLOBAL INVESTORS LP 10% Owner 10% Owner Jan 04 Sell 19.53 540,000 10,546,200 4,247,914 01/05/24
Bizily Scott Chief Legal and HR O.. Chief Legal and HR Officer Jun 08 Sell 20.85 3,750 78,188 1,737 06/12/23
Bizily Scott Chief Legal and HR O.. Chief Legal and HR Officer Jun 08 Option 8.04 3,750 30,150 5,487 06/12/23
Bizily Scott Chief Legal and HR O.. Chief Legal and HR Officer Jun 01 Sell 18.31 2,247 41,143 1,737 06/06/23
Bizily Scott Chief Legal and HR O.. Chief Legal and HR Officer Jun 01 Option 6.49 1,875 12,169 3,984 06/06/23
Moretti August J Chief Financial Offi.. Chief Financial Officer May 15 Option 9.41 3,000 28,230 11,045 05/16/23
Bizily Scott Chief Legal and HR O.. Chief Legal and HR Officer Apr 21 Sell 20 3,750 75,000 2,109 04/25/23
Bizily Scott Chief Legal and HR O.. Chief Legal and HR Officer Apr 21 Option 8.04 3,750 30,150 5,859 04/25/23
Chacko Jacob Director Director Apr 21 Sell 20.05 5,000 100,250 04/25/23
Chacko Jacob Director Director Apr 21 Option 9.41 5,000 47,050 5,000 04/25/23
Kirn David Chief Executive Offi.. Chief Executive Officer Feb 21 Sell 20.88 34,446 719,232 1,859,153 02/23/23
Kirn David Chief Executive Offi.. Chief Executive Officer Jan 19 Sell 20.11 19,524 392,628 1,893,599 01/23/23
Moretti August J Chief Financial Offi.. Chief Financial Officer Dec 21 Option 9.41 3,000 28,230 6,595 12/22/22
Kirn David Chief Executive Offi.. Chief Executive Officer Dec 15 Sell 23.44 86,877 2,036,397 1,913,123 12/19/22
Bizily Scott Chief Legal and HR O.. Chief Legal and HR Officer Dec 01 Option 7.27 5,625 40,894 6,607 12/05/22
Bizily Scott Chief Legal and HR O.. Chief Legal and HR Officer Dec 01 Sell 23.22 6,000 139,320 2,482 12/05/22
SCHAFFER DAVID Director Director Oct 20 Sell 31.19 36,285 1,131,729 901,215 10/22/21